Follicular lymphoma · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Obinutuzumab monotherapy Variant #06 | — | R 190 790 | 21d | — | — | ~7 | ~R 476 974 indirect | — |
Bendamustine and Obinutuzumab Variant #02 | — | R 101 593 | 28d | — | — | ~6 | ~R 227 981 PFS proxy · indirect | 2 |
Bendamustine monotherapy Variant #01 | — | R 7 084 | — | ~16.5 mo | — | ~6 | ~R 42 504 PFS proxy · indirect | 2 |
Ibritumomab tiuxetan protocol Variant #18 Partial | — | — | 8d | ~36.5 mo | — | ~1 | — | 1 |
4 of 4 regimens shown